//=time() ?>
SGLT2 inhibitors in CVD ca. 2022 from @NEJM #Nephpearls #Cardiorenal
https://t.co/Y6xGd4wNgo
SGLT2 inhibitors in CVD ca. 2022 from @NEJM #Nephpearls #Cardiorenal
https://t.co/Y6xGd4wNgo
CHERNEY: Characteristics of participants enrolled in renal outcome trials involving SGLT2 inhibitors
EMPA-KIDNEY ⏳⌛️
🔲 +/- Type 2 DM (T2D)
🔲 eGFR ~ 20
🔲 Low levels of albuminuria
#ISNWCN 🇲🇾 #Nephpearls
👉 https://t.co/R8rVmrqwAf
CHERNEY: Characteristics of participants enrolled in renal outcome trials involving SGLT2 inhibitors
EMPA-KIDNEY (still ongoing)
🔲 +/- Type 2 Diabetes
🔲 eGFR ~ 20
🔲 Low levels of albuminuria
#KidneyWk #Nephpearls
https://t.co/VEBssUX9pV
Our November issue is now live online, featuring #menopausal hormone therapy, #GLP-1 receptor agonists & #SGLT2 inhibitors in #T2D, #Cushing’s disease, metabolic health in the #MENA region, familial #hypercholesterolaemia & #hypertriglyceridaemia, & more https://t.co/ft8CFDeSQz